The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft ...
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...